Nowadays, three of the four drugsadministered for AD approved by the U.S. Food and Drug Administrationare acetylcholinesterase inhibitors (AChEIs).6 Enhancing the cholinergic transmission produces modest but statisticallysignificant improvements in the cognitive and global functions inmild to moderate AD.7 The gene discussed is ACHE; the disease is Alzheimer disease.